INHIBITION OF HIV-1 AND HIV-2 WITH ANTISENSE OLIGONUCLEOTIDES AND RIBOZYMES

硫代修饰的反义寡核苷酸(ASO)已经被 设计成与多种调控和结构基因互补 HIV-1。这些ASO的抗艾滋病毒活性正在接受评估，使用 以H9和U937细胞为靶细胞。抗病毒活性正在评估中 P24抗原和聚合酶链式反应。初步结果表明，ASOS来自 TAT和LTR区对病毒的抑制作用最强 表情。这些ASO被包装成脂质体 单独给药或与其他ASO或AZT联合给药 对靶细胞及其抗病毒活性进行评价。类似 目前正在进行HIV-2病毒的实验。寡核苷酸，允许 核酶复合体的形成或与b-带相互作用 DNA上的基序也在评估它们的抗病毒活性 对抗HIV-1和HIV-2。

Phosphorothioate modified antisense oligonucleotides (ASOs) have been designed complementary to various regulatory and structural genes of HIV-1. These ASOs are being evaluated for their anti-HIV activity using H9 and U937 cells as target cells. Antiviral activity is being assessed by p24 antigen and PCR. Preliminary results suggest that ASOs from the tat and the LTR regions were most effective in inhibiting virus expression. These ASOs are being packaged into liposomes and administered either singly or in combination with other ASOs or with AZT to target cells and their antiviral activity evaluated. Similar experiments are being performed with HIV-2. Oligonucleotides that allow the formation of ribozyme complexes or that interact with b-ribbon motifs on DNA are also being evaluated for their antiviral activity against HIV-1 and HIV-2.